Tab%252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520rizatriptan

# Rizatriptan ## Overview Rizatriptan is a selective serotonin 5-HT1B/1D receptor agonist (triptan) used for the acute treatment of migraine. It induces vasoconstriction of intracranial blood vessels and inhibits the release of pro-inflammatory neuropeptides. ## Primary Indications Acute treatment of migraine, with or without aura, in adults and pediatric patients (aged 6–17 years). ## Adult Dosing * **Initial Dose:** 5 mg or 10 mg. * **Administration:** If the migraine returns or fails to respond, a second dose may be administered at least 2 hours after the first. * **Maximum Dose:** Do not exceed 30 mg in a 24-hour period. * **Note:** Use the 5 mg dose for patients receiving propranolol (due to increased rizatriptan plasma concentrations). ## Pediatric Dosing * **Weight < 40 kg:** 5 mg once per 24-hour period. * **Weight ≥ 40 kg:** 10 mg once per 24-hour period. * **Note:** Safety and efficacy for repeat dosing in a 24-hour period have not been established in pediatric patients; follow local institutional guidelines. ## Dose Adjustments * **Renal/Hepatic Impairment:** Use with caution in patients with mild-to-moderate impairment. Avoid use in severe hepatic or renal impairment. * **Propranolol Concomitant Use:** Maximum dose is 5 mg (max 3 doses/24 hours, though 15 mg total/24 hours is standard limit). ## Contraindications * History of ischemic heart disease (e.g., angina, MI, silent ischemia). * Coronary artery vasospasm (Prinzmetal's angina). * Wolff-Parkinson-White syndrome or arrhythmias associated with accessory conduction pathways. * History of stroke or transient ischemic attack (TIA). * Peripheral vascular disease. * Ischemic bowel disease. * Uncontrolled hypertension. * Administration within 24 hours of another 5-HT1 agonist or ergotamine-type medication. * Administration within 2 weeks of MAO inhibitor therapy. ## Adverse Effects * **Common:** Paresthesia, somnolence, dizziness, fatigue, and pain/tightness in the chest, neck, or throat (triptan sensations). * **Serious:** Coronary artery vasospasm, myocardial ischemia, arrhythmias, serotonin syndrome, and medication overuse headache. ## Key Drug Interactions * **MAO Inhibitors:** Risk of serotonin syndrome and increased rizatriptan levels; avoid combination. * **Propranolol:** Increases rizatriptan AUC by ~70%; requires dosage reduction. * **Selective Serotonin Reuptake Inhibitors (SSRIs/SNRIs):** May increase risk of serotonin syndrome; monitor closely. * **Ergot-containing drugs:** Additive vasoconstrictive effects; avoid within 24 hours. ## Monitoring * Monitor cardiovascular status, especially in patients with cardiovascular risk factors (e.g., postmenopausal women, men >40, uncontrolled hypertension). * Assess for symptoms of serotonin syndrome (agitation, tachycardia, hyperreflexia). * Observe for signs of medication overuse headache (frequent use >10 days/month). ## Clinical Pearls * **Oral Disintegrating Tablets (ODT):** Should be placed on the tongue and allowed to dissolve; no water is required. The blister pack should be kept dry and opened with dry hands. * **Efficacy:** Effectiveness is best when taken at the earliest onset of migraine symptoms. * **Triptan Sensations:** Patients should be counseled that chest/throat tightness is usually transient and non-cardiac in origin, but persistent or severe chest pain warrants immediate medical evaluation. *** *Disclaimer: This information is for educational purposes only. Clinical practice guidelines and drug information can change. Always verify the most current prescribing information, package inserts, and institutional protocols before prescribing or administering medication.*